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The human immunodeficiency virus type 1 (HIV-1) Tat protein enhances reverse transcription, but it is not
known whether Tat acts directly on the reverse transcription complex or through indirect mechanisms. Since
processing of Tat by HIV protease (PR) might mask its presence and, at least in part, explain this lack of data,
we asked whether Tat can be cleaved by PR. We used a rabbit reticulocyte lysate (RRL) system to make Tat
and PR. HIV-1 PR is expressed as a Gag-Pol fusion protein, and a PR-inactivated Gag-Pol is also expressed
as a control. We showed that Tat is specifically cleaved in the presence of PR, producing a protein of
approximately 5 kDa. This result suggested that the cleavage site was located in or near the Tat basic domain
(amino acids 49 to 57), which we have previously shown to be important in reverse transcription. We created
a panel of alanine-scanning mutations from amino acids 45 to 54 in Tat and evaluated functional parameters,
including transactivation, reverse transcription, and cleavage by HIV-1 PR. We showed that amino acids 49 to
52 (RKKR) are absolutely required for Tat function in reverse transcription, that mutation of this domain
blocks cleavage by HIV-1 PR, and that other pairwise mutations in this region modulate reverse transcription
and proteolysis in strikingly similar degrees. Mutation of Tat Y47G48 to AA also down-regulated Tat-
stimulated reverse transcription but had little effect on transactivation or proteolysis by HIV PR, suggesting
that Y47 is critical for reverse transcription. We altered the tat gene of the laboratory strain NL4-3 to Y47D and
Y47N so that overlapping reading frames were not affected and showed that Y47D greatly diminished virus
replication and conveyed a reverse transcription defect. We hypothesize that a novel, cleaved form of Tat is
present in the virion and that it requires Y47 for its role in support of efficient reverse transcription.
The role of Tat in reverse transcription has been a source of
some controversy. When human immunodeficiency virus type 1
(HIV-1) in which the tat gene has functionally been deleted
(tat) is rendered competent for tat-independent gene expres-
sion using heterologous gene activators, the virus remains in-
capable of robust replication (13). In addition, amino acid
substitutions in Tat, such as Y47H, which maintain 45 to 95%
of wild-type transactivation levels, depending on the cell type,
produce markedly delayed replication kinetics after infection
of susceptible cells (24). These observations indicate that Tat is
involved in viral processes other than transactivation of gene
expression. One of these processes appears to be reverse tran-
scription, since following cell infection, HIV-1tat synthesizes
reduced levels of viral DNA relative to the wild-type virus (9).
This defect can be transcomplemented by expressing Tat in the
virus producer cell, but not in the target cell; fully restored
reverse transcription can be achieved with the first 60 amino
acids of Tat. Transcomplementation in this manner stimulates
the production of minus-strand strong-stop (SS) DNA by four-
to eightfold in both cell infection and natural endogenous
reverse transcription (NERT) assays. Moreover, a C27S mu-
tation in Tat blocks transactivation of the HIV-1 long terminal
repeat (LTR) but not transcomplementation of reverse tran-
scription (22). Biochemical analysis of tat virions has not
revealed an obvious defect. Kameoka et al. recently demon-
strated RNA dimerization and stability defects in virions sup-
plied with one-exon but not two-exon Tat, but some of these
studies are complicated by the absence of Nef, a putative virion
maturation factor, in the one-exon Tat but not in the two-exon
Tat viruses (15). They also showed that in vitro reverse tran-
scription reactions are suppressed by 86-amino-acid Tat, but
not 72-amino-acid Tat, which also has apparent HIV nucleo-
capsid-like RNA chaperone activity (14, 15). The role of this
activity in virions is not clear. Taken together, these observa-
tions imply that Tat acts directly on the reverse transcription
reaction and is a virion protein, but this has yet to be demon-
strated.
Since Tat has not been found in purified virions thus far and
given that HIV-1 protease (PR) can cleave proteins with di-
verse amino acid sequences, we asked in the present study
whether Tat can be cleaved by HIV-1 PR into fragments which
might escape detection. We found that in fact Tat could be
cleaved by HIV PR in vitro and in cell culture. Since we have
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previously reported that reverse transcription is at least partly
dependent on the Tat basic domain, we next asked whether
mutations in this domain affect cleavage by PR. We also asked
whether amino acid residues that flank the basic domain, mu-
tations in which do not abolish transactivation but have been
reported to delay the replication cycle in T cells, also contrib-
ute to reverse transcription and/or cleavage by PR. We found
that Tat amino acids 49 to 52 did contribute to the role played
by Tat in reverse transcription and that there was a striking
correlation between the efficiency with which PR cleaved Tat
proteins with mutations in the basic domain or flanking se-
quence and the ability of each mutant to enhance reverse
transcription. The sole exception to this latter observation was
that tyrosine 47 was required for full Tat function in reverse
transcription in both cell infection and NERT but did not af-
fect PR cleavage of Tat. Mutation of Y47 to aspartic acid (which
preserves overlapping reading frames) greatly reduced virus
replication but did not substantially affect transcription. On the
basis of these results, we hypothesize that Tat is a reverse
transcription accessory factor, that this activity is regulated by
PR, and that the cleaved form of Tat is a virion protein which
requires Y47 for its function in reverse transcription.
MATERIALS AND METHODS
Plasmids and constructs. Amino acids in 72-amino-acid TatSF2 (Tat from SF2)
were mutated by site-directed mutagenesis as indicated in Fig. 2 using the
QuikChange method (Stratagene, Inc.). The wild-type or mutated tat genes were
ligated in frame with the green fluorescent protein (GFP) gene gfp (pSFV-GFP
was a gift from Alex Kromykh) at the carboxy-terminal region and cloned into
pBK-RSV (Stratagene, Inc.) and pTM1 vectors. The native tatSF2 gene was also
ligated into the pTM1 vector. The tat gene from HIV-1NL4.3, contained in a
1.6-kb EcoRI/NheI subgenomic DNA fragment from pNL4.3 and ligated into
pGem3z (Promega), was mutated by single-nucleotide alteration to Y47D and
Y47N. All constructs were verified by DNA sequencing. HIV-1 PR was expressed
from a construct (BH10-FS-MscI) containing a frameshift mutation that by-
passes the Gag termination codon (10) and allows continuous expression of
Gag-Pol; this construct also carries an internal deletion created by excision of an
1.9-kb MscI fragment. A second construct, BH10-FS-MscI-PR(), contained an
additional D125R point mutation in PR. SstI/SalI DNA fragments from these
constructs were ligated separately into pGem3z so that the gag-pol reading frame
could be transcribed under the control of the T7 promoter. Plasmid pCH110
(Amersham) was used to express -galactosidase in cell culture transfection
experiments.
Cell lines and viruses. Virus stocks were grown in stably or transiently trans-
fected 293 or 293T cells or in H9 cells. Transient transfections were performed
using Lipofectamine 2000 transfection reagent (Invitrogen) according to the
manufacturer’s instructions, and the generation of stable transfectant cell lines is
described elsewhere (8). Cell lines were assessed for Tat-GFP expression by
fluorescence microscopy, and HIV-1 production was assessed by measurement of
HIV-1 capsid p24 (CAp24) antigen expression in an enzyme-linked immunosor-
bent assay (ELISA) (Perkin-Elmer). A relative fluorescence level was calculated
using cell lysates. Briefly, cells were resuspended in lysis buffer (50 mM Tris-HCl
[pH 8.0], 1.0% Triton X-100, 2 Complete [Roche] protease inhibitor with 10
mM EDTA) on ice, and cell debris was pelleted by centrifugation (25,000  g)
for 30 min. The level of Tat-GFP fluorescence was measured in 100 g of protein
using a Spectrafluor Plus fluorometer (Tecan) and compared to a standard
fluorescence index determined using normal cell lysate containing recombinant
GFP. Tat expression was confirmed by reverse transcription-PCR as described
elsewhere (23). At least four stably transfected 293HIVtat cell lines were
chosen. H9 cells were cultured in RPMI 1640 medium supplemented with 10%
fetal bovine serum and 1% penicillin or streptomycin. 293 cells were cultured in
complete Iscove’s modified Dulbecco’s medium (IMDM) (IMDM with 5% new-
born calf serum, 2% fetal bovine serum, 1% glutamine, and 1% penicillin-
streptomycin). All cells were grown in a humidified 5% CO2 atmosphere at 37°C.
Virus stocks were collected 24 to 48 h posttransfection or, in the case of stable
transfectants, 24 to 48 h after splitting the cells into fresh medium. Virus stocks
were collected in normal growth medium or in serum-free medium (SFM II;
Invitrogen). All virus stocks were filtered through 0.45-m-pore-size membranes
and stored in aliquots at 80°C.
Cell culture transfections and virus infection assays. HeLa, 293, 293T, or H9
cells were transfected with the Tat or Tat-GFP expression plasmids or NL4.3
proviral constructs described above together with an HIV-1 LTR-chloramphen-
icol acetyltransferase (CAT) reporter plasmid. All transfections included
pCH110 and used the Lipofectamine 2000 system (Invitrogen). Cell culture
supernatants were collected 48 h posttransfection and filtered and stored as
described above, and the cells were washed with phosphate-buffered saline
(PBS), resuspended in 200 l of 0.25 M Tris-HCl (pH 7.8), and lysed by repeated
freeze-thaw cycles. Cell lysates prepared in this manner were used in assays of
total protein content and -galactosidase activity. The protein content of cell
lysates was measured using a modified Bradford assay (Bio-Rad). -Galactosi-
dase activity was determined using a chlorophenol red galactopyranoside assay
(12). CAT activity was measured using the Roche Diagnostics CAT ELISA kit.
For single-cycle and continuous infection experiments, aliquots of virus (90
mU of reverse transcriptase activity) were supplemented with 10 mM MgCl2 and
20 U of DNase I (Worthington Biochemical) per ml and incubated at 37°C for
30 to 60 min. Heat-inactivated control aliquots were then incubated at 60°C for
a further 20 min. The DNase I-treated virus aliquots were used to infect 2  107
H9 cells for 2 h, after which the cells were washed three times with culture
medium to remove residual virus. Low-molecular-mass nucleic acids (Hirt lysate)
were isolated from half of the cells immediately and from the remaining cells
after a further 22-h incubation at 37°C. These nucleic acids were resuspended in
stop solution containing MgCl2 (methyl methanesulfonate [MMS], 6 mM Tris-
HCl [pH 7.4], 6 mM EDTA, 12 g of sheared salmon sperm DNA per ml, 4 mM
MgCl2) and assayed for viral DNA by PCR as described below. Continuous
infection experiments were performed in a similar manner. Cell-free viral super-
natant was supplemented with 10 mM MgCl2 and 20 U of DNase I per ml,
incubated at 37°C for 30 min, and then used to infect 5  105 H9 cells in six-well
plates. Twenty-four hours later, the cells were washed three times in media to
remove excess virus and replated in six-well plates. Virus supernatants were
collected every 3 or 4 days for up to 28 days and assayed for CAp24 antigen
expression to monitor replication kinetics. Day 21 supernatants were used to
infect naive H9 cells which were monitored for CAp24 production by ELISA
(Perkin-Elmer). Chromosomal DNA was isolated from the cells when productive
infection became apparent (ca. day 10). The tat gene was amplified from this
chromosomal template by PCR and sequenced by direct PCR sequencing.
NERT-PCR assay. NERT reactions were performed as previously described
(11). Viral DNA was assayed by PCR (25 to 30 cycles of PCR, with 1 cycle
consisting of 2 min at 65°C and 1 min at 93°C) using Platinum Taq DNA
polymerase (Invitrogen) with the reaction buffer supplied and combinations of
HIV-1-specific oligonucleotides. One primer in each pair was labeled with 32P
using [-32P]ATP and T4 polynucleotide kinase, and the reaction products were
resolved on 10% polyacrylamide–Tris-borate-EDTA gels. The gels were dried
and analyzed using a PhosphorImager and ImageQuant software (Molecular
Dynamics). PCR standard curves were generated using proviral plasmids serially
diluted in MMS, and samples were adjusted to the linear range of the PCR
(approximately 50 to 3,500 copies) by serial twofold dilution in MMS. Data sets
in which the linear correlation coefficient of the standard curve was less than 0.98
were discarded.
In vitro translation and protease assays. Proteins were synthesized from the
pTM1, BH10-FS-MscI, and BH10-FS-MscI-PR() constructs described above
using the TNT coupled reticulocyte lysate system (Promega). Reactions (50 l)
were performed according to the manufacturer’s instructions using either 1 g of
PTM1 construct or 8 g of BH10-FS-MscI constructs. Synthesized proteins were
labeled when necessary using Redivue PRO-MIX [35S] cell labeling mix (Am-
ersham Biosciences). Following synthesis at 30°C for 90 min, Tat and Tat-GFP
proteins were mixed with wild-type or mutant PR at 1:8 ratio in separate reaction
mixtures and incubated overnight at room temperature. Proteins were separated
on 12.5% (for Tat-GFP) or 15% (for Tat) polyacrylamide–Tris-borate-EDTA
gels and visualized and quantitated on a PhosphorImager (Molecular Dynamics).
In some experiments, an HIV-1 PR inhibitor (Calbiochem) was added at 900 nM
or Complete protease inhibitor (Roche) was added at 1 to 5 the recom-
mended amount to both PR and Tat-GFP lysates after initial synthesis, and the
mixture was incubated for 1 h before mixing.
Western blots and immunoprecipitation. Stable cell lines expressing Tat-GFP,
wild-type Tat, or Tat-M8, and known to express high levels of GFP and CAp24,
were grown to confluency in complete IMDM supplemented with 1.0 mg of G418
per ml and 0.25 g of puromycin per ml. Cells expressing wild-type Tat-GFP
were seeded onto 6-cm-diameter dishes and grown to confluence in the presence
of 0.6 to 2.4 M concentration of HIV-1 protease inhibitor (Calbiochem). The
cells were harvested, washed once with sterile PBS, resuspended in 200 l of cold
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FIG. 1. Tat can be cleaved by HIV-1 PR in vitro. (A) Wild-type (WT) PR and the inactive D125G mutant were all made in separate RRL
reaction mixtures and then mixed as shown and separated by SDS-PAGE after overnight incubation. HIV-1 PR inhibitor was added () or not
() as indicated below the lane. The results were visualized and analyzed on a Molecular Dynamics PhosphorImager. Tat was bound by a Tat-
specific monoclonal antibody (anti-Tat) but not by a monoclonal antibody for -galactosidase (anti--gal). (B) Eukaryotic expression plasmids
expressing Tat, Tat-GFP, or GFP alone were transfected into HeLa cells along with HIV-LTR CAT and -galactosidase reporter plasmid. CAT
activity was normalized to -galactosidase activity per unit of total protein. 293HIVtat cells were transfected using the same plasmids to compare
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PBS containing1% Triton X-100 and protease cocktail inhibitor (Roche), and
centrifuged at 4°C to remove debris. The supernatant was collected and stored at
80°C. Cell lysate samples were resolved on sodium dodecyl sulfate (SDS)–
12.5% polyacrylamide gels, and the proteins were transferred to polyvinylidene
difluoride and probed with either human anti-HIV-1 immunoglobulin G (IgG)
(National Institutes of Health [NIH] AIDS Research and Reference Reagent
Program [ARRRP] catalog no. 192; diluted 1:6,000), HIV-1BH10 Tat monoclonal
antibody (NIH ARRRP catalog no. 15.1), or anti-GFP rabbit serum (Molecular
Probes catalog no. A6455; diluted 1:5,000). Secondary antibodies were horse-
radish peroxidase (HRP)-coupled goat anti-human IgG (Sigma; diluted 1:6000),
HRP-coupled sheep anti-mouse IgG (heavy plus light chains) (Selinus; diluted
1:2,000), or HRP-coupled goat anti-rabbit IgG (heavy plus light chains) (Zymed;
diluted 1:1,000). Immunoblots were developed using enhanced chemilumines-
cence (SuperSignal; Pierce) and visualized by autoradiography. Dynabeads
M-450 with sheep anti-mouse IgG (Dynal) were used for immunoprecipitation
experiments. The bead-bound Tat was boiled in protein gel loading buffer (60
mM Tris-HCl [pH 6.8], 0.5% SDS, 0.75 mM bromophenol blue, and 100 mM
dithiothreitol), samples were resolved on SDS–15% polyacrylamide gels and
visualized and quantitated on a PhosphorImager (Molecular Dynamics).
RESULTS
Tat is cleaved by HIV-1 PR in vitro, and this cleavage re-
quires the Tat basic domain. A RRL system was used to
examine whether HIV-1 Tat could be cleaved by the viral PR,
which is an in vitro system which demonstrates efficient auto-
processing and folding of PR into an active state (27). Radio-
labeled 72-amino-acid Tat and unlabeled PR (wild type or an
inactive D21R mutant) were made in separate RRL reactions,
mixed as described above, and incubated overnight. The pro-
teins were separated by SDS-polyacrylamide gel electrophore-
sis (PAGE) and analyzed on a Molecular Dynamics Phosphor-
Imager. Figure 1A shows that the amount of 35S-labeled Tat is
dramatically reduced when incubated with lysate containing
PR activity. The 14-kDa protein was confirmed as Tat by
immunoprecipitation using a Tat-specific monoclonal antibody
(Fig. 1A). Large amounts of hemoglobin and other proteins in
RRL made resolving small PR cleavage products impossible.
To overcome this, a tat-gfp fusion gene that maintained trans-
activation activity and efficiently complemented NERT in
HIV-1tat virions was constructed (Fig. 1B). RRL mixing ex-
periments were performed as described above using Tat-GFP.
PR cleavage of the 42-kDa Tat-GFP, which could be inhib-
ited by a PR inhibitor and was not observed when D21R PR
was used, produced a protein of 37 kDa. The HIV-1 PR
inhibitor is reported to inhibit other PRs, cathepsin and pep-
sin, when used at higher concentrations (50% inhibitory con-
centration of 37 and 100 M, respectively). Addition of up to
a 5 level of a broad-spectrum PR inhibitor cocktail to a
mixed-lysate experiment (which inhibits cysteine proteases,
serine proteases, and metalloproteases) did not inhibit cleav-
age of Tat-GFP by HIV-1 PR (Fig. 1C). PR did not cleave
GFP, indicating that PR cleavage of the Tat moiety produced
a cleaved Tat product with an approximate molecular mass of
5 kDa. We have not been able to cleave recombinant Tat with
recombinant HIV-1 PR, both made in Escherichia coli, sug-
gesting that some activity present in or enabled by RRL, such
as protein folding or modification, is required for Tat proteol-
ysis. Our recombinant Tat is made in denaturing conditions
and requires refolding of the protein. It is possible that only a
portion of Tat was folded correctly and may have complicated
the experiment.
On the basis of the 5-kDa shift of Tat-GFP, we estimated
that the PR cleavage point would be located in the vicinity of
the Tat basic domain and made a series of double-alanine-
scanning mutations in the tat-gfp gene from amino acids 45 to
54 (Fig. 1D, M1 to M6). Experiments were performed using
Tat-GFP RRL lysates that contained nearly identical amounts
of wild-type or mutant Tat-GFP that was carefully quantitated
using SDS-PAGE–PhosphorImager and ImageQuant analysis
of radiolabeled protein. As shown in Fig. 2A, wild-type Tat-
GFP, M1, and M2 were efficiently cleaved by PR, whereas M3,
M4, and M5 were consistently resistant to cleavage and M6 was
cleaved at about half the efficiency observed for wild-type Tat-
GFP, indicating that amino acids 49 to 52 were important for
PR cleavage. Two additional Tat-GFP mutations were highly
resistant to cleavage: a Tat basic domain substitution mutant
(M8) and M7, which encompassed amino acids 49 to 52.
Amino acids 49 to 51 were changed from RKK to KRR (M9),
but this had no effect on PR-directed Tat proteolysis. As PR
cleaves between hydrophobic and/or aromatic amino acid res-
idues, we made M10 which replaced amino acids K50 and K51
with asparagine (neutral charge at pH 7.0). M10 was also
resistant to cleavage by PR at levels similar to M3, M4, and
M5. The relative efficiencies of PR cleavage of all Tat-GFP
proteins are shown in Fig. 2A, and these results suggest that
the PR cleavage site is located between amino acids 49 and 52.
Tat is cleaved by PR in cell culture. We previously reported
that HIV-1 Tat improved the efficiency of minus-strand SS DNA
synthesis using a transcomplementation system (9, 12, 22).
Briefly, we made a 293 cell line stably transfected with HIV-1
with a functional deletion of the tat gene, called 293HIVtat.
293HIVtat cells were transfected with each Tat-GFP expres-
sion plasmid, and clonal cell lines stably expressing Tat-GFP
were isolated. Four different G418-resistant cell lines express-
ing wild-type or mutated Tat-GFP genes were selected on the
basis of cell line viability, morphology, and viral reverse tran-
scriptase production. All cell lines were selected by fluores-
cence microscopy, and the levels of Tat-GFP present in whole-
cell lysates made from the cell lines were measured with a
fluorometer to determine relative fluorescence levels (Fig. 2B).
To determine whether Tat-GFP was cleaved in cells,
whole-cell protein lysates were made from freshly confluent
293HIVtat cells complemented with Tat-GFP or with the
the abilities of Tat and Tat-GFP to support efficient reverse transcription. Virus was harvested 48 h posttransfection and normalized to total reverse
transcriptase content using a homopolymer-template reverse transcriptase assay, and minus-strand SS DNA synthesis was measured by NERT-
PCR assay. For both experiments, the mean values and standard deviations (error bars) calculated from three independent experiments are shown.
(C) Experiment was performed as described above for panel A, except that 35S-labeled Tat-GFP and unlabeled HIV-1 PR were preincubated with
increasing concentrations of Complete protease inhibitor for 60 min, mixed as described in Materials and Methods, and separated by SDS-PAGE
after overnight incubation. The results were visualized and analyzed on a Molecular Dynamics PhosphorImager. (D) Schematic of Tat amino acids
45 to 57. The wild-type amino acid sequence is shown above the position numbers, and the mutants used throughout the present study are indicated
below.
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FIG. 2. Cleavage of wild-type (WT) and mutant HIV-1 Tat-GFP proteins by PR. (A) For each PR cleavage assay, 35S-labeled wild-type and
mutant Tat-GFP proteins were synthesized in RRL translation reaction mixtures, and equivalent amounts of the Tat-GFP proteins were mixed as
indicated with unlabeled wild-type (plus-strand) or mutant (minus-strand) HIV-1 PR made in separate RRL reaction mixtures. Each experiment
was repeated three to six times, and the mean result with standard deviation (error bar) is shown. The level of proteolysis was calculated by
comparing the ratio of full-length to cleaved wild-type Tat-GFP protein to the ratio of full-length to cleaved mutant protein. The results were
analyzed on a Molecular Dynamics PhosphorImager. (B) Virus stocks were prepared from two independent cell lines making HIV-1tat virus and
stably transcomplemented with wild-type (WT) or mutant Tat-GFP; the parent cell line is shown as tat. The efficiency of minus-strand SS DNA
synthesis in HIV-1 made in stably transfected cell lines expressing wild-type or mutated tat was determined by NERT-PCR assays. The level of
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Tat-GFP mutant M8 (as M8 demonstrated strong resistance to
cleavage by PR in the RRL system), and Western blots of these
lysates were probed with a monoclonal antibody directed
against GFP and with a human anti-HIV-1 polyclonal anti-
body. We chose 293HIVtat cells complemented with M8, as
these cells produced high levels of virus and Tat-GFP (Fig.
2B). We found that the anti-GFP antibody detected three
proteins in 293HIVtat cells expressing Tat-GFP, one with an
apparent molecular mass corresponding to that of full-length
Tat-GFP and two smaller proteins with similar but distinct
mobilities (Fig. 2D). In contrast, the anti-GFP antibody de-
tected only full-length M8 and one smaller protein, the latter
at a level much lower than that of wild-type Tat-GFP. We
examined whole-cell lysates made from three independent
293HIVtat cell lines stably expressing M8 and obtained very
similar results in all three. Interestingly, whereas Tat-GFP and
M8 made in RRL showed similar mobilities on SDS-polyacryl-
amide gels, M8 made in cells had a lower apparent molecular
mass than that of Tat-GFP, although the size of the cleavage
product was unchanged. The change in mobility of Tat-GFP
compared to that of M8 are likely due to protein modifications
as Tat can be both acetylated (on K28, K50, and K51) and
phosphorylated (S62, T64, and S68 by PKR and requires an
intact tat basic domain) (2, 5, 16–19). Western blotting with an
anti-HIV-1 polyclonal antibody confirmed that all cell lines
expressed similar levels of HIV-1 proteins, including CAp24,
which indicates the presence of active PR in these cells.
The efficiency of Tat cleavage by PR correlates with the
ability to support efficient reverse transcription. Cell-free virus
supernatant was used to determine the ability of selected virus
to initiate NERT. Supernatants containing equivalent amounts
of total reverse transcriptase activity (measured using a com-
mercial homopolymer template assay) were supplemented
with deoxynucleoside triphosphates, MgCl2, and DNase I and
incubated at 37°C, and the amount of intravirion minus-strand
SS DNA synthesized was measured by semiquantitative PCR.
We assayed supernatant from four independent cell lines, and
the results from two representative experiments are shown in
Fig. 2B. As reported in a previous study (22), the M8 mutant
did not support efficient reverse transcription, and neither did
M7; M3 and M5 both showed an intermediate ability, slightly
higher than that of M2, to complement NERT (Fig. 2B). Fi-
nally, virus was made in 293HIVtat cells transiently express-
ing the Tat-GFP mutants M2 (for comparison as it was used to
make stably transfected cells), M4, M9, and M10 (Fig. 2C).
-Galactosidase activity was used to normalize for transfection
efficiency. No reverse transcription defect was observed in M9,
while M4 and M10 showed an intermediate defect similar to
that seen in M3 and M5 (Fig. 2C). Taken together, these
results indicate that the role of the basic domain in support of
reverse transcription is dependent on amino acids 49 to 52 and
that this role is supported by alternative basic residues, sug-
gesting that charge is important (although alternative explana-
tions are possible; see Discussion).
Analysis of Tat Y47 mutants: reverse transcription, virus
replication, and in vitro cleavage by PR. Previous studies of
Tat Y47 showed that it was important for HIV-1 replication,
and studies by our group and others showed that it could
modulate gene expression (up to ca. twofold) and reverse tran-
scription (ca. fourfold) (12, 26). Therefore, we asked whether
other mutations of the proviral tat gene at Y47 had similar
effects on replication and/or reverse transcription and whether
these mutations also affected cleavage of Tat by PR.
We mutated the Tat-GFP expression construct and the na-
tive tat gene in NL4.3 proviral DNA, creating plasmid and
proviral forms with Tat Y47D (M11) and Y47N (M12) muta-
tions (Fig. 1C). These mutations do not affect the adjacent rev
translation initiation codon in the NL4.3 viral genome. The
NL4.3 proviral constructs were transfected into 293T and H9
cells along with a control plasmid expressing -galactosidase.
Culture supernatant and cells were harvested 48 h posttrans-
fection, and CAp24 was measured in the supernatants by
ELISA. -Galactosidase activity relative to total cellular pro-
tein was used to normalize for transfection efficiency. Three
independent experiments, one of which is shown in Fig. 3A and
B, gave similar results.
Cell type-dependent differences in gene expression were ob-
served: relative to NL4.3, NL4.3-M11 was measurably and con-
sistently more active in 293T cells than in H9 cells. Consistent
with a previous report (26), NL4.3-M12 did not express CAp24
at levels substantially different from those of NL4.3. All viral
supernatants were also assayed using a quantitative reverse
transcription assay and gave identical results (data not shown).
Cell-free virus was analyzed in NERT-PCR assays, which
showed that NL4.3-M11 virus made in 293T cells synthesized
minus-strand SS DNA at 30% of levels measured in NL4.3,
while levels of minus-strand SS DNA made by NL4.3 and
NL4.3-M12 were similar (Fig. 3C).
We then used equal quantities of the same three viruses
(made by 293T cells), with heat-inactivated virus as controls, to
infect H9 cells. We measured the amount of minus-strand SS
DNA in Hirt lysates of cells 24 h postinfection by semiquan-
titative PCR (Fig. 3D) and found that, consistent with the
NERT-PCR results, NL4.3-M11 made greatly reduced levels
of minus-strand SS DNA compared to NL4.3 and NL4.3-M12.
Finally, H9 cells were infected, and replication was moni-
tored for 3 weeks using a CAp24 ELISA (Fig. 3E). NL4.3 and
NL4.3-M12 replicated with very similar kinetics, although
NL4.3 with M12 demonstrated slightly more robust replica-
tion, while NL4.3 with M11 repeatedly showed a 2- to 3-week
delay in replication kinetics. NL4.3-M11 virus from 21 days
postinfection was then used to infect H9 cells, and the NL4.3
tat gene was amplified by PCR from chromosomes isolated
from these infected H9 cells.
minus-strand SS DNA made by virus transcomplemented with wild-type Tat-GFP was set at 100%. At least three independent virus stocks were
collected and assayed, and a representative experiment is shown. The relative fluorescence level of Tat-GFP made by each cell line is shown below
the graph. NA, not applicable. (C) Virus stocks collected after transient expression of different Tat-GFP plasmids in 293HIVtat cells were assayed
by NERT-PCR. The level of minus-strand SS DNA made by virus transcomplemented with wild-type Tat-GFP was set at 100%. These experiments
were performed three times, and a representative experiment is shown. (D) Western blot analysis of infected 293 cells stably expressing Tat-GFP
using either anti-GFP monoclonal antibody or a purified pooled human anti-HIV-1 polyclonal antibody as indicated.
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DNA sequencing of the 1.5-kb region containing the tat gene
showed that the M11 mutation had reverted to M12 in two
independent infections. No change was observed in either
NL4.3 or NL4.3-M12. While we did not sequence other regions
of the HIV-1 genome, data from our laboratory and others
support that this compensatory mutation is sufficient to sup-
port robust HIV-1 replication (26).
Finally, we assayed whether Tat-GFP M11 and M12 could
be cleaved by HIV-1 PR in vitro. As shown in Fig. 4A, both
were efficiently cleaved by PR in vitro. These experiments
demonstrate that while Y47 has little or no effect on in vitro
cleavage of Tat by PR, it is essential for Tat-enhanced reverse
transcription. To our knowledge, this is the first mutated Tat
protein active in transcription and defective for Tat-enhanced
reverse transcription.
DISCUSSION
HIV-1 reverse transcription is a highly regulated process
which involves a number of virion proteins, including Tat (for
recent reviews, see references 6 and 7). There are two leading
hypotheses regarding the mechanism by which Tat enhances
reverse transcription. The indirect-mechanism hypothesis holds
that Tat’s effect on reverse transcription is the result of changes
in the cellular environment brought about by Tat’s pleiotropic
effects on cellular gene expression (discussed in reference 7).
One possibility is that insufficient and/or dysregulated tran-
scription or translation in the absence of Tat may result in virus
particles that are less competent for reverse transcription and
less infectious. This seems unlikely, since HIV-1tat has low or
reduced replication even when made competent for tat-inde-
FIG. 3. Tat Y47 is critical for virus replication and important for reverse transcription. (A and B) H9 or 293T cells were cotransfected with wild-
type or mutant NL4.3 proviral DNAs along with a -galactosidase reporter plasmid. The amount of CAp24 in the supernatant was measured by
ELISA, normalized to the measured relative transfection efficiency, and expressed relative to the level of CAp24 made by the wild-type (WT) virus.
The experiments were performed at least four times, and a representative experiment is shown for each cell line. (C) Virus stocks were obtained
from the transfected 293 cells and assayed for total reverse transcriptase. NERT-PCR assays were performed using equivalent amounts of total
reverse transcriptase, and the amount of minus-strand SS DNA made by each virus was expressed relative to wild-type (WT) NL4.3. (D) H9 cells
were infected for 2 h with DNase I-treated virus stocks containing 100 ng of CAp24, with or without heat inactivation, and then washed thoroughly.
After a further 22-h incubation, low-molecular-weight DNA was isolated from a portion of each infection and assayed for minus-strand SS DNA
by the same PCR used in NERT-PCR assays. (E) The remaining cells were grown and divided every 2 or 3 days as required. A sample of the culture
supernatant was saved at each cell passage, and the amount of CAp24 was measured by ELISA. A virus stock was collected from the infected cells
on day 21 and used to infect naive H9 cells. The tat gene was amplified by PCR from chromosomes isolated from these cells 10 days postinfection,
and the amplicon was directly sequenced.
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pendent gene expression using alternative gene activators (13,
25), and Tat mutants, such as Y47D or Y47H, which maintain
up to 95% of wild-type transactivation levels still show mark-
edly delayed replication kinetics (26). The direct-mechanism
hypothesis is that Tat itself plays a role in reverse transcription.
Genetic analysis has shown that Tat’s function in reverse tran-
scription is distinct from its role in transcription and requires
only the first 60 amino acids (9). In addition, a C27S mutation
in Tat inactivates transactivation of the viral LTR but supports
reverse transcription (22), while a Y47D mutation inhibits Tat
function in reverse transcription but supports high levels of
gene expression. Together, these results suggest that Tat acts
directly on reverse transcription, which implies that Tat is a
virion protein, although this has never been demonstrated.
This study shows that Tat can be cleaved by HIV-1 PR in
RRL systems and in cell culture, apparently within the basic
domain and most likely in the vicinity of amino acids 49 to 52.
Mutation of any two residues between amino acids 49 and 52
resulted in a four- to five-fold decrease in the efficiency of PR
cleavage, while mutation of all four residues inhibited PR
cleavage almost completely. Interestingly, nuclear magnetic
resonance studies by several groups indicate that the basic
domain adopts a solvent-exposed extended structure that
would be available for proteolytic attack by PR (1, 20). At-
tempts to isolate the 37-kDa Tat-GFP cleavage product from
RRL or transfected cultured cells have not yet produced suf-
ficient purified protein for N-terminal sequence analysis; fur-
ther experiments are in progress. Regardless of the exact cleav-
age site, it seems likely that the small 5- to 6-kDa protein that
results from cleavage of Tat would be present in low abun-
dance in the virion and would be extremely difficult to detect.
This may account for the continuing lack of any direct evidence
for Tat in the virion. Numerous attempts by our laboratory to
directly detect Tat and cleaved Tat have not succeeded. Our
efforts have been hampered by the lack of adequate anti-Tat
antibodies which were used in this project successfully to de-
tect RRL radiolabeled Tat but were not effective in detecting
Tat-GFP in cell lysates.
Kameoka et al. (14, 15) recently reported that in vitro, two-
exon (86- or 101-amino-acid) but not one-exon (72-amino-
acid) Tat facilitates annealing of the tRNAlys3 primer to the
viral RNA and suppresses reverse transcriptase elongation. In
apparent contrast, our genetic complementation studies with
72-amino-acid Tat all point to Tat activation of reverse tran-
scription. These observations may be reconciled if PR is re-
quired to cleave Tat so that reverse transcription may proceed
and if full-length two-exon Tat impedes premature DNA syn-
thesis (which may be detrimental to completion of the virus life
cycle). In this model, 72-amino-acid Tat would be less inhibi-
tory than the two-exon form but still unable to enhance reverse
transcription until cleaved by PR. The present study provides
further evidence for this model, since there was a striking cor-
relation between the ability of PR to cleave Tat basic domain
mutants and the ability of those mutants to support reverse
transcription (Table 1). The only exception was the mutant
M2, which is readily explained if the cleavage site is down-
stream of Y47.
FIG. 4. Tat-GFP Y47 is not important for Tat cleavage by PR.
RRL mixing experiments were performed as described in the text. (A)
35S-labeled wild-type (WT) Tat-GFP or mutant Tat-GFP (M11 and
M12) and unlabeled HIV-1 wild-type () and inactive mutant () PR
were all made separately in RRL and mixed as shown above the lanes.
The mixed lysates were separated by SDS-PAGE after overnight in-
cubation, and the results were analyzed on a Molecular Dynamics
PhosphorImager. Each experiment was repeated three to six times,
and a representative experiment is shown. (B) The level of proteolysis
in panel A was calculated as described in the legend to Fig. 2 and
expressed relative to the level observed in wild-type (WT) Tat-GFP.
TABLE 1. Comparison of Tat-GFP activity in reverse
transcription and cleavage by PR
tat gene
Minus-strand SS DNA
levelc Cleavage by
PRc, g
NERTd Hirtf
M1a NT 
M2a  
M3a  
M4a  
M5a  
M6a  
M7a  
M8a  
M9a  
M10a  
M11a  
M12a  
NL4.3 e 
NL4.3 M11b e 
NL4.3 M12b e 
a tat gene derived from HIV-1SF2 and fused to GFP.
b Point mutation in proviral DNA of HIV-1NL4.3 tat gene.
c , 	50% wild-type level; , 	15% wild-type level; , wild-type level;

, 15% wild-type level; NT, not tested.
d Amount of minus-strand SS DNA made by NERT of HIV-1 transcomple-
mented with transfected Tat-GFP.
e Amount of minus-strand SS DNA made by NERT of NL4.3 with a mutated
tat gene.
f Amount of minus-strand SS DNA made by NL4.3 with a mutated tat gene
after single-cycle infection of H9 cells.
g Measurements based on PR cleavage of Tat-GFP in an RRL system.
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Tat amino acids 49 to 52 and the flanking sequences repre-
sent a novel PR cleavage site, as PR typically cleaves between
hydrophobic or hydrophobic and aromatic amino acid resi-
dues. To the best of our knowledge, cleavage by PR at basic
amino acid residues has not been described. Repeated at-
tempts to cleave Tat made in E. coli with PR have not been
successful, suggesting that Tat made in RRL is somehow qual-
itatively different. RRL is competent for many posttransla-
tional modifications, including glycosylation, prenylation, N
acetylation, mryistolyation, and phosphorylation, and is also
known to have chaperone activity. PR activity at basic residues
might require modification of lysine 50 and 51 by acetylation,
making these residues hydrophobic (3, 4, 16, 19). Experiments
are in progress to determine whether Tat is acetylated in RRL
using antibodies directed to acetyl-lysine and by labeling Tat
with 14C-labeled acetyl coenzyme A in RRL.
An alternative protein modification pathway, such as argi-
nine methylation, cannot be excluded and could contribute to
cleavage of PR by Tat. Two classes of protein arginine meth-
yltransferases have been characterized. Type I arginine meth-
yltransferases account for formation of asymmetric NG,NG-
dimethyl-arginine, and type II arginine methyltransferases
catalyze the formation of symmetric NG,NG-dimethyl-arginine.
While the methylation motif is generally RRG or RXG,
STAT1 was shown to be methylated on R31 (EIRQY) by
PRMT1 which regulated STAT1 transcriptional activity (18).
To our knowledge, there are no reported studies of Tat meth-
ylation on arginine residues. To some extent, acetylation of Tat
within amino acids 49 to 52 would represent a conundrum, as
such a modified Tat molecule would not traffic to virions on the
plasma membrane by binding to TAR RNA, which is an ob-
vious mechanism through which Tat could be targeted to the
virion. In cells, Tat is mostly located in the nucleolus, although
Tat trafficking through the cytoplasm has been demonstrated
(21). It is possible that TAR RNA binding lacks sufficient
specificity, as all HIV-1 mRNAs contain TAR RNA structures
and could divert limiting quantities of cytoplasmic Tat to in-
appropriate subcellular locations.
Alternative possible mechanisms of Tat trafficking might
include Tat binding to a virion protein (such as pr160gag,
pr55gag, or vpr) or to a cellular protein, such as cyclophilin A,
which is packaged in virions. A previous study showed that
60-amino-acid Tat (amino acids 1 to 60), but not 53-amino-acid
Tat (amino acids 1 to 53), could transcomplement tat-deficient
virus, indicating that the entire basic domain was required (9).
One possibility is that the basic domain (modified by acetyla-
tion or maybe by methylation) interacts with a viral or cellular
protein which is targeted to the virion. Once in the virion,
maturation of the virion particle by PR could cleave Tat.
Finally, this study confirms previous reports that Tat Y47
was essential for virus replication in H9 cells and further
showed that a Y47D mutation in Tat imparted a significant
reverse transcription defect that, in conjunction with a small
gene expression defect, impeded virus replication (12, 26). Our
data indicate that the reduced viral fitness observed by Verhoef
et al. (26) was likely due to combined inefficiencies in tran-
scription and reverse transcription. The NL4.3-M11 virus used
in this study was made by changing only a single DNA base
from UAT (tyrosine) to GAT (aspartic acid), and replicating
virus obtained after 21 days had undergone a single compen-
satory mutation to AAT (asparagine) which supported efficient
virus replication in H9 cells. These data imply that Y47D
imparted a significant impedance to virus replication and high-
light the importance of TatY47. Whether this residue is im-
portant for intra- or interprotein interaction or whether it
facilitates primer annealing to the HIV template is not known
and requires further study.
Although the precise mechanism of Tat-enhanced reverse
transcription is not known, these and other studies indicate
that impeding Tat function in reverse transcription imparts a
significant defect in virus replication, making Tat a viable tar-
get for antiretroviral drug design. In particular, if the PR-
cleaved form of Tat is active in reverse transcription, this
molecule may represent a novel target for drug screening and
design.
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